MYX mayne pharma group limited

What MYX chart shouts, page-261

  1. 7,700 Posts.
    lightbulb Created with Sketch. 630
    To be realistic I'm not expecting NPAT 15% for the next 1-2 years, as the ship is just turning.
    Sustainable Revenue growth is the most significant sign of positive, outlook suggest FY25 will way overpass the $400-450m revenue mark, as revenue increase the Direct Opex will be substantially lower and the margin will rise further.
    Also the 2nd half net loss includes the $33m settlement payout and the Earn-out payment, so the real loss is much lower.
    When approach NPAT break-even the ratio of less than 1 ( revenum $400-450m vs MC $370)will be screamingly cheap.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.28
Change
0.060(1.15%)
Mkt cap ! $426.5M
Open High Low Value Volume
$5.29 $5.29 $5.15 $45.47K 8.702K

Buyers (Bids)

No. Vol. Price($)
8 491 $5.26
 

Sellers (Offers)

Price($) Vol. No.
$5.28 183 4
View Market Depth
Last trade - 11.57am 18/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.